For instance, in metastatic uveal melanoma, the combined application of HDACi Entinostat and PD-1 inhibitor Pembrolizumab has been validated to exert durable responses of tumor regression and prolonged survival in a phase 2 clinical trial, especially for patients with low tumor burden and BAP1 wildtype tumors (124). Here, BAP1 is linked to neoplasm.